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What’s already known about this topic?  
PUVA is widely used for the treatment of topical steroid resistant hand eczema. Despite the 
widespread use of NBUVB for whole body eczema there have been few investigations of 
NBUVB for hand eczema. Small studies have shown it to be safe but formal comparison with 
PUVA by RCT has not been performed. 
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 What does this study add? 
This pilot study suggests that both immersion PUVA and NBUVB are effective treatments for 
palmar hand eczema. NBUVB appears more likely to cause mild side effects such as 
erythema. NBUVB for hand eczema is a safe and reasonable alternative to PUVA. 
Recruitment of sufficient numbers of patients to a non-inferiority study comparing PUVA 
with NBUVB may be challenging.  
 
Summary 
Background: Hand eczema is a common inflammatory dermatosis that causes significant 
patient morbidity. Symptoms such as pain, itch and localised swelling contribute to 
disruption of activities of daily living, lack of sleep, and missed days from work. The 
aetiology is often multifactorial. Previous studies comparing psoralen ultraviolet A (PUVA) 
and narrowband ultraviolet B (NBUVB) have been small, non-randomised and retrospective. 
 
Objectives: To conduct an observer blinded randomized controlled pilot study using 
validated scoring criteria to compare immersion PUVA with NBUVB for the treatment of 
chronic hand eczema unresponsive to topical steroids.  
 
Methods: 60 patients (22 male, 38 female), median age 50 years (range 22, 73), with hand 
eczema unresponsive to clobetasol propionate 0.05% (Dermovate®) (25 (42%) severe), were 
randomised to receive either immersion PUVA (n=30) or NBUVB (n=30) twice weekly for 12 
weeks with assessments at intervals of 4 weeks. The primary outcome measure was the 
proportion of patients achieving a ‘clear’ or ‘almost clear’ Physician’s Global Assessment 
(PGA) treatment response at 12 weeks. Secondary outcome measures included assessment 
of the modified Total Lesion and Symptom Score (mTLSS) and the Dermatology Life Quality 
index (DLQI)  
 
Results: In both treatment arms, 23 patients completed the 12-week assessment for the 
primary outcome measure. In the PUVA group, 5 patients achieved ‘clear’, and 8 ‘almost 
clear’ (ITT response rate 43% (95%CI: 26%, 61%)). In the NB-UVB group, 2 achieved ‘clear’ 
and 5 ‘almost clear’ (ITT response rate 23% (95%CI: 8%, 38%)). For the secondary outcomes, 
median (IQR) mTLSS scores were similar between groups at baseline (PUVA 9.5 (6.8,11), 
NBUVB 9 (6.8,12)) and at 12-weeks (PUVA 3 (1,6), NBUVB 4(2,8)). Changes in DLQI were 
similar with improvements in both groups.  
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Conclusions: In this randomised pilot trial recruitment was challenging. Once randomised, 
there were acceptable levels of compliance and safety in each treatment schedule, but 
lower levels of retention. Using validated scoring systems; PGA, mTLSS and DLQI as 
measures of treatment response, the trial demonstrated that both PUVA and NBUVB 
improved the severity of chronic palmar hand eczema. The study was not designed to 
demonstrate superiority of one treatment and a larger adequately powered RCT will be 
required to investigate this.   
 
Introduction: 
Hand eczema (HE) is a common, relapsing inflammatory dermatosis characterised clinically 
by erythema, scaling, fissures, swelling and vesiculation1. It is a condition that causes 
significant patient morbidity, with symptoms such as pain, itch and burning contributing to 
insomnia, disruption of activities of daily living and work absenteeism2. The Scandinavian 
TOACS study estimate an incidence of 8.8 per 1000 persons per year, with a history of atopic 
dermatitis being the most significant risk factor3. Meding et al reported that up to 21% of 
patients take at least one period of absence of at least 7 days from work, and that 8% of 
patients will change their occupation due to hand eczema severity4. HE classification can be 
based on aetiology or morphology; with common sub-types including atopic, irritant 
contact, allergic contact, pompholyx, hyperkeratotic or mixed. Following failure of topical 
treatment, systemic therapy or phototherapy is often needed.  
Phototherapy has several advantages over oral systemic treatment; no blood monitoring is 
required and avoidance of side effects associated with retinoids or immunosuppressant 
medication. Disadvantages include equipment setup and staffing costs, multiple patient 
hospital visits, risk of skin erythema and burning, and the potential to induce photo-damage 
and cutaneous malignancy.  
Following the introduction of psoralen ultraviolet A (PUVA) for psoriasis, the use of PUVA for 
hand eczema emerged in the 1980s without any large scale clinical trials. The efficacy of 
narrowband ultraviolet B (NBUVB) for generalised atopic eczema has been demonstrated in 
RCTs5. The use of NBUVB for HE has been advocated by some Dermatologists but is not 
widespread. Studies comparing PUVA vs NBUVB for HE have been small, non randomised, 
retrospective and have often included other non-eczematous dermatoses. More 
importantly, standardised skin severity scoring systems were  not  used6-9. Perhaps due to 
concerns that hand  NBUVB may not penetrate palmar skin and possible problems with  
erythema, PUVA has remained the phototherapy treatment of choice for hand eczema. 
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We identified a need to formally compare NBUVB with PUVA for HE in a prospective, 
randomised setting using validated scores. NBUVB has potential logistic advantages, 
including cheaper costs and faster patient turnaround time (no hand soaking required and 
shorter irradiation times) or avoidance of potential side effects if oral PUVA is used. If 
NBUVB were equivalent or superior to PUVA there would be a strong case to use it as first 
line treatment. We report  the first randomised observer blinded pilot study to compare 
NBUVB vs immersion PUVA using validated outcome measurements.  
 
Methods 
The trial was conducted as single centre, observer blinded, prospective, randomised pilot 
trial. The primary objective was to demonstrate feasibility to recruit, treat and retain 
patients and obtain accurate data defining the clinical response of HE to NBUVB and 
immersion PUVA. Patients were recruited from clinics at Newcastle Dermatology at the 
Newcastle Hospitals NHS Trust. The department has 16 clinics per day and treats around 
1000 patients per week. Hand eczema was diagnosed by history and examination and 
biopsies were not taken. 
 
Eligibility and Exclusion Criteria 
Patient eligibility and exclusion criteria are shown in Table 1. Eligibility included palmar hand 
eczema only to minimise the dosing complexity that would have been needed with different 
doses required for the thinner skin on the dorsal surfaces. One of the main inclusion criteria 
was “Not responding to topical treatments” targeting patients who, after treatment by a 
Dermatologist with standard topical treatments, had not improved and needed second line 
treatments. In practice, this will have included non-response to super potent topical steroids 
and often tacrolimus although there were not defined rules regarding prior treatment 
choices. Patients with mild eczema elsewhere on the body were eligible but those with 
more widespread eczema where palmar eczema was not the predominant problem were 
excluded from the study. 
 
Randomisation and treatment details 
Patients were randomised on a 1:1 basis using a random block allocation method, stratified 
by gender and eczema severity (Physicians global assessment(PGA) severe vs 
mild/moderate). Randomisation was administered centrally by a secure web-based system 
and the schedule produced by a statistician not involved with the trial.  Flow of patients 
through the trial is shown in Figure 1. Patients were randomised into 2 groups as follows: 
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Group 1 (standard treatment) received immersion PUVA twice weekly.  Patients' hands 
were immersed in psoralen solution (0.5ml of 1.2% 8-methoxypsoralen in 2L tap water) for 
15 minutes followed by exposure to UVA radiation at an initial dose of 0.5 J/cm2 according 
to British Photo-dermatology Group (BPG) guidelines10. Doses were then increased for each 
treatment (1.0, 1.5, 2, 3, 4, 5, 6). The maximum dose was 6 J/cm2 and the maximum 
potential cumulative dose 125 J/cm2 (incremental doses over 3 weeks plus 18 treatments 
x6J/cm2).  
 
Group 2 (intervention treatment) received NBUVB twice weekly. Initial doses were 0.5 J/cm2 
and increased by 20% increments to a maximum of 10 J/cm2. The maximum potential 
cumulative dose was 123 J/cm2 . 
Phototherapy was delivered using Waldmann 181 units fitted with UVA or NBUVB bulbs. 
The devices were calibrated and maintained throughout the trial by the medical physics 
department at Newcastle Hospitals NHS Trust. 
For both groups doses were reduced if erythema developed. Once symptoms had settled 
patients were re-started at the last dose that had been tolerated without side effects.  Trial 
exit criteria for both groups were completing 12 weeks of treatment (24 separate 
treatments) or attaining 'clear' or 'almost clear' as defined by the Physicians Global 
Assessment (PGA) score. Patients were permitted to use unlimited emollients during the 
trial and had to stop using topical steroids for 48h before trial commencement and their 
first dose of UV irradiation. To allow for missed appointments, but avoid major disruption to 
dosing schedules, we allowed patients to complete their 12 weeks of treatment within a 
maximum 14-week time frame 
 
 Outcome measures 
The primary outcome measure was the proportion of patients achieving a PGA ‘clear’ or 
‘almost clear’ treatment response at 12 weeks (or at their last visit if they achieved this 
before 12 weeks). The ‘index hand’ was defined as either the worst affected hand at 
baseline or if both hands were the same at baseline, the hand with the best response was 
analysed for the primary outcome. The PGA score is described by Ruzicka et al11. 
Secondary outcome measures included (1) the modified total lesion severity score (mTLSS), 
a score with 7 components scored at 0 to 3 with a maximum of 21; (2) the patient reported 
Dermatology Life Quality Index (DLQI), a validated measure of the effect of skin disease on 
patient’s daily activities and (3) safety measures.  
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The choice of outcome measures was influenced by those used in the largest randomised 
trial of hand eczema investigating the efficacy and safety of alitretinoin11. In this trial, the 
PGA scoring was interpreted such that a patient could be classified as ‘severe’ either by 
symptoms or involved surface area criteria.  
A final outcome measure was feasibility, defined as the number of patients randomised as a 
proportion of the number of potential eligible participants.  
 
Hand eczema severity assessments and Blinding 
At randomisation HE types, duration, presence at other sites, previous therapeutic 
interventions, and pre-existing medical conditions were recorded. At randomisation and at 
weeks 4, 8 and 12, patient HE severity (PGA and mTLSS) was independently assessed by one 
of 2 clinicians who were blinded to the treatment modality being used; whilst the attending 
nursing staff and patients receiving treatment were unblinded. The assessing clinicians were 
trained in utilising the PGA and mTLSS using standardised photographs of HE severity and 
real patients to improve parity12. Patients were examined before their treatments in a 
closed office in an area of the department separate from the phototherapy equipment. At 
baseline, and each subsequent visit DLQI was determined via patient questionnaire.   
 
Sample size and statistical analysis plan 
 As a pilot study, the sample size was chosen as an achievable target based on the minimum 
conventional threshold for making parameter estimates in pilot studies13, aiming to recruit 
60 patients with baseline and 12 week scores. Allowing for 20% potential drop-outs and loss 
to follow up inflated the recruitment target to a total of 76 patients.  
As a pilot study, the statistical analyses are focussed on descriptive statistics reporting 
primarily feasibility and response rates on an intention-to-treat (ITT) basis. Feasibility is 
calculated as the number of patients randomised as a proportion of the number of potential 
eligible participants. The primary outcome measure was PGA response rate at 12 weeks 
calculated as the number of ‘clear’ or ‘almost clear’ responders as a proportion of the 
number of patients randomised. Additional per protocol PGA response rates are reported as 
a planned sensitivity analysis. Longitudinal data, including PGA and mTLSS scores, are 
plotted over time. Patients with PGA response are assessed for duration of response. 
Patient reported quality of life is scored according to the Dermatology Life Quality Index 
(DLQI) and reported descriptively over time14. 
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Adverse event documentation 
Expected phototherapy related side-effects include various grades of erythema. Adverse 
events were recorded and graded on a three-point severity scale of mild, moderate and 
severe; whilst causality for each event was assessed as unrelated, unlikely, possible, probable, 
definite or not assessable. (Mild: Discomfort noted with no disruption of activities of daily 
living (ADLs). Moderate: Discomfort sufficient to limit normal ADLs. Severe: Incapacitating 
discomfort with inability to work or perform ADLs.) The number of patients experiencing at 
least one severe episode is reported as a percentage of the total number of patients receiving 
treatment and as the total number of patients randomised. 
 
Results 
Recruitment and Randomisation 
From August 2012 to April 2014, 105 patients were assessed via dedicated trial recruitment 
clinics where the diagnosis and categorisation of patients’ hand eczema was made by a 
consultant dermatologist; 105 patients were screened; 73 patients fulfilled the eligibility 
criteria and 32 were excluded (Supplementary Table 1). 13 eligible patients declined to 
enter mainly (69%) due to inability to commit to twice weekly visits, travel difficulties and 
issues with work commitments. Three of the 13 were not entered due to specifically 
requesting PUVA treatment.  A total of 60 patients were consented and randomised: 38 
(63%) were female, 25 (42%) with severe disease, approximately balanced across 
randomised treatment groups through stratification. Feasibility, as assessed by recruitment 
rate, was 82.2% (95%CI: 73.4%, 91.0%.).  The total number of patients randomised was 
lower than the target of 76 due to difficulties to recruit and subsequent time and financial 
limitations.   
 
Patient Demographics  
 The predominant type of HE was hyperkeratotic (47%). The median (range) duration of HE 
was 2.5 (0.3, 35) years, with 42% reporting eczema at body sites other than their hands 
(Table 2). It is unusual for there to be no cases of contact eczema reported. Patch testing 
was not part of the protocol and no analysis has been done based on subtype. We reported 
predominant HE type and it is possible that some patients may have had a contribution to 
their disease from contact allergy. In a full study it would be important to document contact 
allergy accurately with patch testing of all participants. None of the randomised patients 
had previously tried any systemic therapy for their hand eczema.  
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Treatment Received and Adverse Events 
One patient randomised to PUVA decided not to participate in the study and did not start 
treatment.  Median (IQR) number of treatments was 24 (17, 24) for the 29 PUVA patients 
and 22 (16, 24) for the 30 NBUVB patients (Supplementary Table 2). Most patients began 
treatment immediately and time on treatment was on average 85 days, in line with the 
protocol. Median (IQR) cumulative dose was 105.5 (66.0, 111.5) J/cm2 for the 29 PUVA 
patients and 60.7 (28.1, 92.0) J/cm2 for the 30 NBUVB patients.  
A total of 54 adverse events were reported in 29 (49%) patients (Supplementary Table 3). Of 
these, 37 (PUVA n=10 (19%), NBUVB n=27, (50%)) were classed as mild (discomfort noted, 
no disruption to ADLs). A total of 17 moderate or severe events were reported in 13 (22%) 
patients; 14 events in 10 patients were in the NBUVB group (none were severe, 8 were 
treatment related) and 3 events in 3 patients were in the PUVA group (1 severe, none 
treatment related). Most of the NBUVB adverse events were predictable due to erythema or 
burning. There was one reported serious adverse event in the NBUVB arm due to abdominal 
pain requiring admission which was judged to be unrelated to the trial treatment. 
 
Primary outcome measure: PGA 
The PGA scores at baseline for the index hand were 11 (18%) mild, 24 (40%) moderate and 
25 (42%) severe (Table 3). A total of 46 (77%) patients (23 in each randomised group) had 
final assessment data available for analysis. The most common reason for patients not 
reaching the end of the study was being unable to attend assessments due to work 
commitments. A total of 13 patients randomised to PUVA had PGA response at 12-week 
assessment (5 clear, 8 almost clear). A total of 7 patients randomised to NBUVB had PGA 
response at 12-week assessment (2 clear, 5 almost clear) (Table 3).  Intention-to-treat 
analysis (ITT) PGA response rates demonstrated 43% (95%CI: 26%, 61%) response in the 
PUVA group and 23% (95%CI: 8%, 38%) in the NBUVB group. A planned per-protocol 
sensitivity analysis of the primary outcome measure demonstrated a 57% (95%CI: 36%, 77%) 
and 30% (95%CI: 12%, 49%) PGA response for PUVA and NBUVB respectively (Table 3).  
 
Secondary outcome measures 
The secondary outcome measures were recorded at baseline, week 4, week 8 and at the 
end of the study (week 12-14). Median mTLSS scores decreased during the treatment period 
in both randomised groups (Figure 2) where decreased score indicates decreased severity. 
The sizes of reductions were similar in both groups:  median (IQR) mTLSS scores at 
randomisation and end of study were 9.5 (6.8, 12) and 3 (1, 6) for PUVA; 9 (6.8, 11) and 4 (2, 
8) for NBUVB.  
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There was a marked reduction in mTLSS scores for both treatments in patients who 
achieved the primary PGA response compared to those patients who did not 
(Supplementary Figure 1). 
There was a progressive reduction in DLQI in both groups over time where reduced DLQI 
indicates improving quality of life (Figure 3). The size of the reductions was similar in both 
groups:  median (IQR) DLQI scores at randomisation and end of study were 9.5 (7.8, 15.5) 
and 2 (0, 11) for PUVA; 10.5 (7, 16) and 4 (2, 7) for NBUVB. 
Only 19 patients (32%) were followed to the 26 weeks follow up due to lack of patient 
availability giving too small a data set for meaningful analysis. 
 
Discussion  
We have conducted a pilot study investigating NBUVB and  immersion PUVA for the 
treatment of palmar hand eczema resistant to topical therapy. Both treatment modalities 
were shown to be safe with good patient acceptability. The higher rate of treatment related 
AE in the NBUVB group was not unexpected. NBUVB is more likely to cause erythema than 
PUVA. The degree of erythema experienced by an individual patient is related to dose but 
also epidermal thickness, UV penetration, local factors which influence photoadaptation 
and biochemical factors influencing erythema. No patients withdrew from the study due to 
AE; however, further work on dosimetry may succeed in reducing the episodes of NBUVB 
mediated erythema.  
Almost twice as many patients in the PUVA group (43%, 95%CI: 26%, 61%) achieved the 
primary outcome (clear or almost clear PGA) compared with the NBUVB group (23%, 95% CI: 
8%, 38%), although with wide over-lapping confidence intervals. A similar difference was not 
seen in the mTLSS and DLQI data. The mTLSS is a 21-point score and provides a more 
sensitive and detailed description of the hand eczema severity. Patients with only small 
differences in the mTLSS can be allocated different PGA scores. The categorical nature of the 
PGA score may therefore amplify the differences between groups. We recommend that 
future studies use a scoring system with a continuous measurement as the primary outcome 
measure, rather than the categorical PGA.  As with the mTLSS, the DLQI scores were similar 
between both groups suggesting that the large PGA determined primary outcome 
difference is possibly misleading.  Due to the relatively small size of the study firm 
conclusions cannot be made on response by hand eczema subtype. However, the majority 
of patients had hyperkeratotic hand eczema and their thickened epidermis may have 
influenced the penetration of the UV with UVA penetrating more readily than UVB. Any 
future studies will need to carefully balance the groups for HE types. 
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 The design of this trial was in part based on the Ruziicka et al alitretinoin study11. In 
retrospect, a better primary outcome would have been a continuous scale such as , the 
HECSI (Hand eczema clinical severity index)15. Advantages of the HECSI include more 
accurate recording of area involved and a lack of subjective measures such as itch but the 
disadvantage is increased complexity and a longer scoring time. Future studies could 
consider its use in addition to PGA, mTLSS and DLQI. 
For ethical reasons, there was no control group and it is therefore possible that some 
patient improvement may have been through regression to their mean severity values (i.e. 
recruited at their most severe and through the natural fluctuation of inflammatory skin 
disease were better 12 weeks later at the end of the trial). However, clinical experience of 
patients with severe chronic hand eczema suggests that without treatment most remain 
severely affected and so most improvements seen in this study are likely to be a result of 
the interventions. One option would be to only treat one hand and monitor the untreated 
hand for any concomitant severity changes although HE is often asymmetric in severity 
which limits this study design. 
The literature regarding phototherapy for hand eczema is fragmented, consisting of small, 
non-randomised studies, retrospective case series and inclusion of patients with non-
eczematous dermatoses; making it difficult to draw definite conclusions regarding best 
practice. Numerous small studies have demonstrated the benefits of PUVA for hand eczema 
and are consistent with the wide clinical experience of this treatment16-18. There have been 
other comparisons of PUVA vs UVB but most of the studies were small and did not use 
validated scoring systems. Rosen et al  compared broadband UVB with oral PUVA in a 
randomised, non-blinded study that recruited 35 patients with various forms 
(predominantly ACD) of hand eczema18. Using a non-validated scoring method, they 
concluded that oral PUVA was superior to UVB treatment. However, it is unlikely that the 
sample size used was sufficient to make a statistically significant conclusion.  
In 1997 Simons et al performed a right-left comparison of topical PUVA vs NBUVB in 13 
patients with chronic hand eczema and concluded that there was no statistical difference in 
efficacy, although the PUVA treated hands suffered more episodes of burning17. In 2007, 
Sezer et al  performed a randomised, prospective right-left comparison study on 15 patients 
with chronic hand eczema, treating them with either immersion PUVA or NBUVB 3 times a 
week for 9 weeks with similar results seen  for both treatments9.  
Adhering to standard dosimetry schedules, the short-term safety profile of both therapies 
appears limited to episodes of erythema. However, the long-term safety of repeated 
treatment courses to the hands is yet to be elucidated for both immersion PUVA and 
NBUVB. Further work is needed to investigate the optimal dosing regimen for NBUVB in HE. 
Whilst this study only treated the palms, the thinner dorsal surfaces may be more prone to 
erythema and careful investigation will be needed to determine the starting doses and 
increments when using NBUVB in this area. 
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Ultimately, a non-inferiority study comparing PUVA against NBUVB would help to determine 
the order of treatment choice. This would be challenging due to patient numbers required 
to provide sufficient statistical power. The introduction of an effective  licensed oral agent 
for hand eczema ,alitretinoin, may also lead to a reduced demand for phototherapy. The UK 
NIHR is currently conducting the ALPHA study comparing PUVA vs alitretinoin and these 
results may also have a big impact on treatment choice and the current widespread use of 
phototherapy for HE19. For these reasons, the need for a definitive non-inferiority trial  of 
NBUVB vs immersion PUVA  will be reviewed following the results of ALPHA.  
This randomised pilot trial has confirmed feasible levels of randomisation and retention, 
acceptable treatment schedules demonstrating high compliance and acceptable safety 
profiles for each arm. It has quantified the variation in disease. This trial has shown that 
whilst NBUVB did result in more frequent episodes of erythema, overall it was safe and well 
tolerated and did produce improvements for some patients. Immersion PUVA was well 
tolerated. NBUVB is proposed as a safe treatment option for patients desiring a shorter 
hospital visit for their treatment or when PUVA has not been effective. Further investigation 
is needed to determine if one treatment is superior to the other.  
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Table 1.  
 
Inclusion criteria Exclusion criteria
Written informed consent 
Palmar eczema not responding to topical treatments 
Any type of hand eczema 
Over 18 years of age 
No systemic treatments for 3 months 
 
Inability to give informed consent. 
Significant eczema on the dorsal surface of the hands  
Phototherapy within the last 3 months 
Sunbed use within the last 3 months 
Current involvement in other investigational studies  
Pregnant 
Clinical evidence of infection 
 
 
  
Table 1 
Inclusion and exclusion criteria for study.  
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Table 2 
 
 
Table 2   Patient Characteristics at Randomisation 
 
 
 PUVA NBUVB Total 
n=30 n=30 n=60 
Sex                                Male 
Female 
12 (40%) 
18 (60%) 
 10 (33%) 
20 (67%) 
 22 (37%) 
38 (63%) 
 
Severity                       Severe   
Mild /moderate 
12 (40%)
18 (60%) 
13 (43%)
17 (57%) 
25 (42%) 
35 (58%) 
Age                     Median (yrs) 
Range 
IQR 
51 
(22, 73) 
(33, 61) 
44
(22, 72) 
(34, 61) 
50 
(22, 73) 
(34, 61) 
Predominant type of HE          
Allergic Contact Dermatitis 
Irritant Contact Dermatitis 
Allergic and Irritant 
Atopic HE 
Atopic and Irritant 
Vesicular 
Hyperkeratotic 
 
0 (0%) 
5 (17%) 
1 (3%) 
4 (13%) 
4 (13%) 
2 (7%) 
14 (47%) 
0 (0%) 
3 (10%) 
1 (3%) 
5 (17%) 
3 (10%) 
4 (13%) 
14 (47%) 
 
0 (0%) 
8 (13%) 
2 (3%) 
9 (15%) 
7 (12%) 
6(10%) 
28(47%) 
Duration: years 
Median (Range) 
 
2 (0.5,35) 2.75 (0.3,10) 
 
2.5(0.3,35) 
Eczema at other sites       No 
                                             Yes 
20 (67%) 
10 (33%) 
15 (50%) 
15 (50%) 
35 (58%) 
25(42%) 
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Table 3  
Number of patients reaching clear or almost clear on the PGA score at the end of the study 
(shaded). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 PGA Score at Baseline 
 
 0. Clear 1. Almost  2. Mild 3. Mod 4. Severe Total  
PUVA 0 0 4 15 11 30 
NBUVB 0 0 7 9 14 30 
TOTAL 0 0 11 24 25 60 
   
 Final PGA Response  
 0. Clear 1. Almost  2. Mild 3. Mod 4. Severe Total  
PUVA 5 8 3 4 3 23 
NBUVB 2 5 10 5 1 23 
TOTAL 7 13 13 9 4 46 
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Table 3 b) Proportion of patients reaching clear or almost clear on the PGA score at the end of 
the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 % Achieving PGA response at final assessment (95% CI) 
 
 
Intention-to-treat
NBUVB =30, PUVA =30 
Per protocol
NBUVB=23, PUVA=23 
primary outcome response 
PUVA =13 
43% 
(26%, 61%) 
57%
(36%, 77%) 
Primary outcome response 
NBUVB = 7 
23% 
(8%, 38%) 
30%
(12%, 49%) 
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Figure 1  
 
 
 
Screening  and Recruitment
Patients with any type of hand eczema 
affecting the palmar skin 
(n=105) 
Randomisation 
Permutated random block allocation 
Randomisation with stratification by gender 
and a dichotomous variable measuring 
eczema severity (n=60) 
Immersion PUVA 
 
Twice weekly 
24 treatments over 12 weeks 
(n=30) 
NBUVB
 
Twice weekly 
24 treatments over 12 weeks 
(n=30)
Observer blinded clinical 
assessments at 0, 4, 8, 12 weeks 
(n=23) 
Observer blinded clinical 
assessments at 0, 4, 8, 12 weeks 
(n=23)
Drop outs that did not complete 
final assessments (n=7) 
 (includes one that received 
no treatment) 
Drop outs that did not complete 
final assessments 
(n=7)
Ineligible (n=32) 
Eligible (n=73)
Declined (n=13) 
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Figure 1 
The trial flowchart shows the distribution of patients between the two intervention arms of 
the trial. The details of reasons for ineligibility and declining to participate are shown in 
supplementary table 1. 
 
Figure 2 
Boxplots of patient’s mTLSS score at baseline, week 4, week 8 and final assessment at week 12 (max 
14 weeks) for NBUVB (blue) and PUVA (grey). Boxplots show median (band inside box), the 
interquartile range (top and bottom of box), whiskers extend to 1.5 X IQR and outliers (asterisk). The 
mTLSS is a hand eczema score with 7 components scored at 0 to 3 with a maximum of 21. Median 
mTLSS scores decreased during the treatment period in both randomised groups 
 
   
Median mTLSS scores and (IQR) for patients with baseline PGA scores 
 
Arm Baseline: median 
(IQR) 
Wk4: median 
(IQR) 
Wk8: median 
(IQR) 
Final: median 
(IQR) 
NBUVB 9 (6.8,11) 7 (4,10) 5 (3,8) 4 (2,8)
PUVA 9.5 (6.8,12) 8 (6,10.75) 6 (3.3,10.8) 3 (1,6)
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Figure 3  
Boxplots of patient’s DLQI score at baseline, week 4, week 8 and final assessment at week 12 (max 
14 weeks) for NBUVB (blue) and PUVA (grey). Boxplots show median (band inside box), the 
interquartile range (top and bottom of box), whiskers extend to 1.5 X IQR and outliers (asterisks). 
Reductions in DLQI were seen in both groups over the course of the 12 weeks. 
 
 
Median DLQI score and (IQR) patients with baseline PGA scores. 
 
Arm Baseline: 
median (IQR) 
Wk4: median 
(IQR) 
Wk8: median 
(IQR) 
Final: median 
(IQR) 
NBUVB 10.5 (7,16) 6 (2,13) 6.5 (2.3,11) 4 (2,7)
PUVA 9.5 (7.8,15.5) 7 (4,12) 5.5 (2,11.5) 2 (0,11)
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